Brogidirsen shows motor benefits and safety over 3.5 years of treatment in people with DMD who are amenable to exon 44 ...

Feeling discouraged by the progression of his FSHD, columnist Robin Stemple focuses on the love and kind gestures he's ...

Three boys with DMD given the gene therapy GNT0004 in a trial showed sustained improvements in motor function after two years ...

Columnist Shalom Lim and his girlfriend, Amanda, were among the disability advocates who let their voices be heard at a ...

Health Canada approved Agamree (vamorolone) to treat Duchenne muscular dystrophy (DMD) in patients ages 4 and older.

By grounding himself in the reasons why he keeps moving forward, columnist Patrick Moeschen is able to figure out how to ...

For boys who start corticosteroids for DMD, being taller is tied with slower growth, and being older is tied to more weight ...

Avidity's exon-skipping therapy del-zota led to functional gains for people with DMD, regardless of their walking abilities, ...

Columnist Betty Vertin's sons with Duchenne MD have seen their social circle shrink over the years, but they now enjoy time with each other.

Satellos Bioscience is planning a Phase 2 trial in the U.S. to test SAT-3247 in children with Duchenne who are able to walk.

The U.S. Food and Drug Administration (FDA) has expanded its approval of Elevidys (delandistrogene moxeparvovec-rokl), authorizing the one-time gene therapy for individuals with Duchenne muscular ...

A young man with Duchenne muscular dystrophy (DMD) who received the one-time gene therapy Elevidys (delandistrogene moxeparvovec-rokl) has died due to acute liver failure. In a statement, the ...